Search research articles
Contact Us
Filters
Showing results (401-410 of 468) with videos related to
Page
of 47
Sort By:
The Lancet. Oncology
|
February 22, 2015
Orteronel plus prednisone in patients with chemotherapy-naive metastatic castration-resistant prostate cancer (ELM-PC 4): a double-blind, multicentre, phase 3, randomised, placebo-controlled trial
Fred Saad, Karim Fizazi, Viorel Jinga, et al.
Nature Communications
|
April 26, 2022
Machine learning-coupled combinatorial mutagenesis enables resource-efficient engineering of CRISPR-Cas9 genome editor activities
Dawn G L Thean, Hoi Yee Chu, John H C Fong, et al.
Molecular Genetics and Metabolism
|
March 1, 2015
Newborn screening for X-linked adrenoleukodystrophy in New York State: diagnostic protocol, surveillance protocol and treatment guidelines
B H Vogel, S E Bradley, D J Adams, et al.
Future Oncology (London, England)
|
February 5, 2014
Randomized Phase II trial of nintedanib, afatinib and sequential combination in castration-resistant prostate cancer
L Rhoda Molife, Aurelius Omlin, Rob J Jones, et al.
Psychosomatic Medicine
|
October 6, 2022
Epigenome-Wide Analysis of DNA Methylation and Optimism in Women and Men
Cuicui Wang, Dawn L DeMeo, Eric S Kim, et al.
European Urology Oncology
|
May 3, 2026
Pembrolizumab Plus Lenvatinib in Participants with Docetaxel-pretreated Metastatic Castration-resistant Prostate Cancer: Results from KEYNOTE-365 Cohort E
Marinela Augustin, Brigitte Laguerre, Capucine Baldini, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 22, 2010
Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval
Peter C Fong, Timothy A Yap, David S Boss, et al.
British Journal of Cancer
|
July 15, 2010
The insulin-like growth factor-I receptor inhibitor figitumumab (CP-751,871) in combination with docetaxel in patients with advanced solid tumours: results of a phase Ib dose-escalation, open-label study
L R Molife, P C Fong, L Paccagnella, et al.
JAMA Neurology
|
December 21, 2019
Association of Cognitive and Behavioral Features Between Adults With Tuberous Sclerosis and Frontotemporal Dementia
Andy J Liu, Adam M Staffaroni, Julio C Rojas-Martinez, et al.
European Urology Focus
|
August 12, 2025
Vibostolimab Coformulated with Pembrolizumab in Participants with Docetaxel-pretreated Metastatic Castration-resistant Prostate Cancer: KEYNOTE-365 Cohort G
Peter C Fong, Mariusz Kwiatkowski, Alessandra Mosca, et al.
Page
of 47
Search research articles
Search
Showing results (401-410 of 468) with videos related to
Sort By:
Page
of 47
The Lancet. Oncology
|
February 22, 2015
Orteronel plus prednisone in patients with chemotherapy-naive metastatic castration-resistant prostate cancer (ELM-PC 4): a double-blind, multicentre, phase 3, randomised, placebo-controlled trial
Fred Saad, Karim Fizazi, Viorel Jinga, et al.
Nature Communications
|
April 26, 2022
Machine learning-coupled combinatorial mutagenesis enables resource-efficient engineering of CRISPR-Cas9 genome editor activities
Dawn G L Thean, Hoi Yee Chu, John H C Fong, et al.
Molecular Genetics and Metabolism
|
March 1, 2015
Newborn screening for X-linked adrenoleukodystrophy in New York State: diagnostic protocol, surveillance protocol and treatment guidelines
B H Vogel, S E Bradley, D J Adams, et al.
Future Oncology (London, England)
|
February 5, 2014
Randomized Phase II trial of nintedanib, afatinib and sequential combination in castration-resistant prostate cancer
L Rhoda Molife, Aurelius Omlin, Rob J Jones, et al.
Psychosomatic Medicine
|
October 6, 2022
Epigenome-Wide Analysis of DNA Methylation and Optimism in Women and Men
Cuicui Wang, Dawn L DeMeo, Eric S Kim, et al.
European Urology Oncology
|
May 3, 2026
Pembrolizumab Plus Lenvatinib in Participants with Docetaxel-pretreated Metastatic Castration-resistant Prostate Cancer: Results from KEYNOTE-365 Cohort E
Marinela Augustin, Brigitte Laguerre, Capucine Baldini, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 22, 2010
Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval
Peter C Fong, Timothy A Yap, David S Boss, et al.
British Journal of Cancer
|
July 15, 2010
The insulin-like growth factor-I receptor inhibitor figitumumab (CP-751,871) in combination with docetaxel in patients with advanced solid tumours: results of a phase Ib dose-escalation, open-label study
L R Molife, P C Fong, L Paccagnella, et al.
JAMA Neurology
|
December 21, 2019
Association of Cognitive and Behavioral Features Between Adults With Tuberous Sclerosis and Frontotemporal Dementia
Andy J Liu, Adam M Staffaroni, Julio C Rojas-Martinez, et al.
European Urology Focus
|
August 12, 2025
Vibostolimab Coformulated with Pembrolizumab in Participants with Docetaxel-pretreated Metastatic Castration-resistant Prostate Cancer: KEYNOTE-365 Cohort G
Peter C Fong, Mariusz Kwiatkowski, Alessandra Mosca, et al.
Page
of 47